SUBSCRIBE
SUBSCRIBE

Jazz Pharmaceuticals, Inc.

NEWS
The Day In Review: Acquisitions Help Biotech
October 19, 2005
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS
IN THE PRESS
Business
Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
April 20, 2022
 · 
1 min read
Drug Development
Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types
April 8, 2022
 · 
6 min read
Business
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
April 7, 2022
 · 
10 min read
Biotech Bay
Jazz Pharmaceuticals to Participate in Upcoming April 2022 Investor Conferences
March 29, 2022
 · 
1 min read
Biotech Bay
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics
March 28, 2022
 · 
12 min read
Deals
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
March 28, 2022
 · 
14 min read
Drug Development
Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors
March 24, 2022
 · 
11 min read
Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting
March 8, 2022
 · 
5 min read
Business
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2021 Financial Results
March 1, 2022
 · 
32 min read
Biotech Bay
Jazz Pharmaceuticals to Participate in Upcoming March 2022 Investor Conferences
February 28, 2022
 · 
1 min read
Load More